Structural Similarities between Some Common Fluorophores Used in Biology, Marketed Drugs, Endogenous Metabolites, and Natural Products

O’Hagan, Steve; Kell, Douglas B.

Published in:
Marine Drugs

Link to article, DOI:
10.3390/md18110582

Publication date:
2020

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):
O’Hagan, S., & Kell, D. B. (2020). Structural Similarities between Some Common Fluorophores Used in Biology, Marketed Drugs, Endogenous Metabolites, and Natural Products. Marine Drugs, 18(11), [582]. https://doi.org/10.3390/md18110582
Structural Similarities between Some Common Fluorophores Used in Biology, Marketed Drugs, Endogenous Metabolites, and Natural Products

Steve O’Hagan 1,2 and Douglas B. Kell 3,4, *

1 Department of Chemistry, The University of Manchester, Manchester M13 9PT, UK; sohagan@manchester.ac.uk
2 Manchester Institute of Biotechnology, The University of Manchester, 131 Princess St, Manchester M1 7DN, UK
3 Department of Biochemistry and Systems Biology, Institute of Molecular, Integrative and Systems Biology, Biosciences Building, University of Liverpool, Crown Street, Liverpool L69 7ZB, UK
4 Novo Nordisk Foundation Centre for Biosustainability, Technical University of Denmark, Building 220, Kemitorvet, 2800 Kongens Lyngby, Denmark

Correspondence: dbk@liv.ac.uk

Received: 8 November 2020; Accepted: 20 November 2020; Published: 23 November 2020

Abstract: It is known that at least some fluorophores can act as ‘surrogate’ substrates for solute carriers (SLCs) involved in pharmaceutical drug uptake, and this promiscuity is taken to reflect at least a certain structural similarity. As part of a comprehensive study seeking the ‘natural’ substrates of ‘orphan’ transporters that also serve to take up pharmaceutical drugs into cells, we have noted that many drugs bear structural similarities to natural products. A cursory inspection of common fluorophores indicates that they too are surprisingly ‘drug-like’, and they also enter at least some cells. Some are also known to be substrates of efflux transporters. Consequently, we sought to assess the structural similarity of common fluorophores to marketed drugs, endogenous mammalian metabolites, and natural products. We used a set of some 150 fluorophores along with standard fingerprinting methods and the Tanimoto similarity metric. Results: The great majority of fluorophores tested exhibited significant similarity (Tanimoto similarity > 0.75) to at least one drug, as judged via descriptor properties (especially their aromaticity, for identifiable reasons that we explain), by molecular fingerprints, by visual inspection, and via the “quantitative estimate of drug likeness” technique. It is concluded that this set of fluorophores does overlap with a significant part of both the drug space and natural products space. Consequently, fluorophores do indeed offer a much wider opportunity than had possibly been realised to be used as surrogate uptake molecules in the competitive or trans-stimulation assay of membrane transporter activities.

Keywords: drugs; natural products; fluorophores; fingerprinting; similarity; cheminformatics; rdkit; Tanimoto distance

1. Introduction

Fluorescence methods have been used in biological research for decades, and their utility remains unabated (e.g., [1–22]). Our specific interest here is in the transporter-mediated means by which small fluorescent molecules enter living cells, and our interest has been stimulated by the recognition that a given probe may be a substrate for a large variety of both influx and efflux transporters [23]. Efflux transporters are often fairly promiscuous, since their job is largely to rid cells of unwanted molecules that may have entered, although they can and do have other, important physiological roles (e.g., [24–34]), and are capable of effluxing a variety of fluorescent probes (e.g., [35–42]). However,
given that most of these probes are contemporary, synthetic molecules, the uptake transporters for which they are substrates are nonetheless often ancient [43,44], and must have evolved in nature for other purposes. These purposes may reasonably be expected to include the uptake of endogenous metabolites in multicellular organisms [45–53], as well as exogenous natural products whose uptake can enhance biological fitness (e.g., [54,55]). This explanation does seem to hold well for synthetic, marketed pharmaceutical drugs [55].

Consequently, it seemed reasonable that existing fluorescent molecules, that are not specifically designed for the purpose but are taken up by biological cells, might also bear structural similarities to endogenous substrates (metabolites) and to natural products (including those from the marine environment), and potentially also to marketed drugs. Of course, some marketed pharmaceutical drugs that are transported into cells are, in fact, naturally fluorescent, including molecules such as anthracyclines [56–58], mepacrine (atebrin, quinacrine) [59], obatoclax [60,61], tetracycline derivatives [57,62] and topotecan [63]. The same is true of certain vitamins such as riboflavin [64,65] (that necessarily have transporters, as cells cannot synthesise them), as well as certain bioactive natural products (e.g., [66–68]). As per this Special Issue, and in an era of increasing antimicrobial resistance [69–72], this is very much the case for novel antimicrobials, which classically come from natural products (e.g., [73–78]).

If so, they might then serve as surrogate transporter substrates for them. Indeed, there are examples—so-called fluorescent false neurotransmitters—where such fluorescent analogues of natural substrates have been designed precisely for this purpose (e.g., [79,80]). The aim of the present work was to assess the extent to which this kind of structural similarity between (i) common fluorophores used in biology and (ii) other molecular classes (endogenous mammalian metabolites, marketed pharmaceutical drugs, and known natural products) might be true. It is concluded that in structural terms, common fluorophores do indeed overlap drug space significantly, and we offer an explanation based on the consonance between aromaticity, conjugated π-bonds, and fluorescence. Such fluorophores might then lend themselves readily to high-throughput assays in which their uptake and/or efflux are studied in the presence and absence of ‘competing’ drugs. A preprint is available [81].

2. Results

Figure 1A shows a Principal Components Analysis (PCA) plot of the distribution of the four classes based on a series of descriptors in RDKit (www.rdkit.org), while Figure 1B shows a t-SNE [82] plot of the same data. These clearly show a strong overlap between the rather limited set of fluorophores used and quite significant parts of the drug space. Figure 1C gives just the fluorophores, with the nominal excitation maximum encoded in its colour. This suggests that even with just ~150 molecules, we have achieved a reasonable coverage of the relevant ‘fluorophore space’, with no obvious bias or trend in excitation wavelengths.

We previously developed the use of rank order plots for summarising the relationships (in terms of Tanimoto similarities) between a candidate molecule or set of molecules and a set of targets in a library [45]. Figure 2 shows such a rank order plot, ranking, for each fluorophore, the most similar molecule in the set of endogenous Recon2 [45,83] metabolites, the set of marketed drugs [45], and a random subset of 2000 of some 150,000 molecules taken [55,84] from the Unified Natural Products Database (UNPD) [85]. This again shows very clearly that the majority of fluorophores chosen do look moderately similar (TS > 0.75) to at least one drug (and even more so to representatives of the natural products database).

It is also convenient [45] to display such data as a heat map [86], where a bicluster is used to cluster similar structures and the colour of the cell at the intersection encodes their Tanimoto similarity. Figure 3 shows such heatmaps for fluorophores vs. (A) endogenous (Recon2 [87]) metabolites, (B) drugs, and (C) 2000 sampled natural products from UNPD. The data reflect those of Figure 2, and it is again clear that for each fluorophore there is almost always a drug or a natural product for which the average Tanimoto similarity is significantly greater than 0.7.
Figure 1. Principal components and t-SNE plots of the principal components of the variance in calculated properties of the molecules used. (A) The first two principal components of the variance in calculated properties of the four classes fluorophores, drugs, metabolites and natural products. Molecules are as in Supplementary Fluorophores SI.xlsx, with the drugs and metabolites those given in [45]. A sampling of 2000 natural products from our download [55] of UNPD was used. Descriptors were z-scores normalised and correlation filtered (threshold 0.98). (B) t-SNE plot of the data in (A), using the same colour-coding. (C) Plot of the first two principal components of the variance in the fluorophores alone. The excitation wavelength is encoded in the colour of the markers. The size of the symbol encodes the molecular weight, indicating that much of the first PC is due to this (plus any other covarying properties).
we provide some illustrations that give a feeling of the kinds of similarity that may be observed. (Figure 4B). Note, of course, that the t-SNE plots are based on property descriptors, while the Tanimoto distances are based on a particular form of molecular fingerprint, so, \textit{a priori}, we do not necessarily expect the closest molecules to be the same in the two cases. In addition, we note that molecules with different scaffolds may be quite similar; in the cheminformatics literature, this is known as \textquoteleft{scaffold hopping\textquoteleft} (e.g., [99–104]).

Fluorescein is similar in t-SNE space (Figure 4A) to a variety of drugs. This similarity is not at all related to the class of drug, however, as close ones include balsalazide (an anti-inflammatory used in inflammatory bowel disease [95]), bentiromide (a peptide used for assessing pancreatic function [96]), butenafine (a topical antifungal [97]), sertindole (an atypical antipsychotic), and tolvaptan (used in autosomal dominant polycystic kidney disease [98]). Similar remarks may be made of dapoxyl (Figure 4B). Note, of course, that the t-SNE plots are based on property descriptors, while the Tanimoto distances are based on a particular form of molecular fingerprint, so, \textit{a priori}, we do not necessarily expect the closest molecules to be the same in the two cases. In addition, we note that molecules with different scaffolds may be quite similar; in the cheminformatics literature, this is known as \textquoteleft{scaffold hopping\textquoteleft} (e.g., [99–104]).

For a drug, we picked nitisinone, a drug active against hereditary tyrosinaemia type I [105] and alkaptonuria [106,107], as it is surrounded in t-SNE space (Figure 4C) by several tricyclic fluorophores, that do indeed share similar structures (Figure 4C).

Bickerton and colleagues [108] introduced the concept of the quantitative estimate of drug-likeness (QED) (however, see [109]), and it is of interest to see how \textquoteleft{drug-like\textquoteleft} our four classes of molecule are based on their criteria. Figure 5A shows the distribution of QED drug-likenesses for marketed drugs, for Recon2 metabolites, for our selected fluorophores, and for a sample of 2000 molecules from UNPD. Our fluorophores are noticeably more similar to drugs than are endogenous metabolites, and roughly as similar to drugs as are natural products (Figure 5A).
Figure 3. Heat maps illustrating the Tanimoto similarities (using the RDKit patterned encoding) between our selected fluorophores and (A) Recon2 metabolites, (B) Drugs, and (C) a subset of 2000 natural products from UNPD.
Figure 4. Observable structural similarities between selected fluorophores and drugs. The chosen molecules are (A) fluorescein, (B) dapoxyl (both fluorophores) and (C) nitisinone (a drug). Data are annotated and/or zoomed from those in Figure 1B.
marketed drugs, for Recon2 metabolites, for our selected fluorophores, and for a sample of 2000 molecules from UNPD. Our fluorophores are noticeably more similar to drugs than are endogenous metabolites, and roughly as similar to drugs as are natural products (Figure 5A).

**Figure 5.** Distribution of quantitative estimate of drug-likeness (QED) values in different classes of molecule. (A). Cumulative distributions for the four classes. (B). Relationship between QED and aromaticity for the four classes as encoded by the fraction of C atoms exhibiting sp$^3$ bonding. QED values were calculated using the RDKit Python code as described in Methods and plotted in (A) using ggplot2 and in (B) using Spotfire. (C). Density distribution of fraction of C atoms with sp$^3$ bonding. (D). Histogram of distributions of numbers of aromatic rings in the four given classes.
Given that essentially all drugs are similar to at least one natural product [55], this is entirely consistent with our thesis that most fluorophores do look rather like one or more of the marketed drugs. One aspect in which (a) drugs and fluorophores differ noticeably from (b) metabolites and natural products is the extent to which they exhibit aromaticity, encoded here (Figure 5B, on the abscissa) via the fraction of carbon atoms showing sp\(^3\) hybridisation (i.e., non-aromatic). This is shown as a distribution in Figure 5C. There is clearly a significant tendency for drugs to include (planar) aromatic rings, and although this is changing somewhat [110–114], there are strong thermodynamic reasons as to why this should be so (see Discussion). The modal number of aromatic rings for both drugs and fluorophores is two, significantly greater than that (zero) for metabolites and for natural products (Figure 5D). One reason for fluorophores to exhibit aromaticity is simple, as reasonable visible-wavelength fluorescence in organic molecules relies greatly on conjugation (e.g., [115]), to which aromatic rings can contribute strongly. This argument alone probably accounts in large measure for the drug-likeness of fluorophores.

Finally, a very recent, principled, and effective clustering method [116,117], representing the state of the art, is that based on the Uniform Manifold Approximation and Projection (UMAP) algorithm. In a similar vein, and based on the same descriptors as used in the t-SNE plots, we show the clustering of our four classes of molecule in UMAP space, where most clusters containing drugs also contain fluorophores. Despite being based on property descriptors, the UMAP algorithm is clearly very effective at clustering molecules into structurally related classes.

3. Discussion

Most drugs can act (often deeply) within the target organism or tissue, and thus the means by which they get to their sites of action is significant. This is considered especially true for natural products which (as with many drugs) normally do not adhere to the ‘rule of 5’ [76,118–127]. The chief answer to the question of how drugs do get through biomembranes is ‘by using SLCs’, and so it would be desirable to have high-throughput methods to assesses the activities of these transporters. Among the commoner approaches are methods that assess the uptake of fluorophores, but these are likely to ‘work’ only if drugs and natural products, including marine drugs, do in fact structurally resemble fluorophores.

The basis of the main idea presented and tested here is that the structures of common fluorophores are in fact sufficiently similar to those of many drugs (including natural products) as to provide suitable surrogates for assessing their uptake via solute carriers of the SLC (and, indeed, their efflux via ABC) families. While the latter transporters are well known to be rather promiscuous, and to transport a variety of fluorophores [40,42,128–130], considerably less attention has been paid to the former. As mentioned in the Introduction, some marketed pharmaceutical drugs that are transported into cells are in fact naturally fluorescent, including anthracyclines [56–58], mepacrine (atebrin, quinacrine) [59], obatoclax [60,61], tetracycline derivatives [57,62] and topotecan [63], while the same is true of certain vitamins riboflavin [64,65] and certain bioactive natural products (e.g., [66–68]). As an illustration, and as a complement to our detailed gene knockout studies [23], Table 1 gives an indication of dyes whose interaction with specific transporters has been demonstrated directly. In some cases, their surrogacy as a substrate for a transporter with a known non-fluorescent substrate is clear, and as mentioned in the introduction, they are sometimes referred to as ‘false fluorescent substrates’. Overall, while not intended to be remotely exhaustive, this Table does serve to indicate the potentially widespread activity of transporters as mediators of fluorophore uptake, and indeed, a number of such transporters are known to be rather promiscuous.
Table 1. Some examples in which fluorescent dyes have been found to interact with uptake transporters directly as substrates or inhibitors. We do not include known non-fluorescent substrates to which a fluorescent tag has been added (see, e.g., [131–133]).

| Dye                                      | Transporter          | Comments                                                                 | Reference |
|------------------------------------------|----------------------|--------------------------------------------------------------------------|-----------|
| Amiloride                                | OCT2 (SLC22A2)       | A drug. Rhodamine 123 and 6G also served as substrates.                  | [134]     |
| 4′,6-diamidino-2-phenylindol (DAPI)      | OCT1 (SLC22A1)       | Potently inhibited by desipramine and also by various organophosphate pesticides. | [135,136] |
| DiBAC(4)3 Na+/HCO3− NBCe1-A SLC4A4       |                      | competition with 4,4′-Diisothiocyanostilbene-2,2′-disulfonic acid         | [137]     |
| 5-carboxyfluorescein                     | OAT3 (SLC22A8)       | Very high V_max                                                          | [94]      |
| 6-carboxyfluorescein                     | OAT1 (SLC22A6)       |                                                                           | [94,138]  |
| 2′,7′-dichlorofluorescein                | OATP1B1 (SLCO1B1)    | Good substrate                                                            | [139]     |
| 4-(4-(Dimethylamino) styryl)-N-methylpyridinium (ASP+) | Dopamine transporter (SLC6A3) |                                                                           | [140,141] |
| Noradrenaline transporter (SLC6A2)      |                      |                                                                           | [140,142,143] |
| Serotonin transporter SLC6A4             |                      |                                                                           | [140,144] |
| Various monoamine transporters           |                      |                                                                           | [145]     |
| OCT1/OCT2 (SLC22A1/2); Various OCT transporters |          | Seen as a model substrate                                               | [146]     |
| Other, unknown (non-OCT1/2) transporters with low affinity |                      |                                                                           | [148]     |
| Ethidium                                 | OCT1/2/3 (SLC22A1/2/3) | Substrate                                                               | [149]     |
| FFN511                                   | VMAT2 (SLC18A2)      | ‘False fluorescent neurotransmitter’ (i.e., surrogate substrates) concept | [79]      |
| FFN54/246                                | SLC6A4, SLC18        | ‘False’ fluorescent substrates for serotonin and VMAT transporters. Potent inhibition by imipramine and citalopram | [80]      |
| FFN270                                   | SLC6A4, SLC18        | Another example of a fluorescent false neurotransmitter                 | [150]     |
| Fluorescein                              | SLCO1B1/3B1          | Effective substrate, analysis of inhibitors                               | [92,93]   |
|                                          | OAT6 (SLC22A20)      |                                                                           | [94]      |
|                                          | SLC16A1, SLC16A4     |                                                                           | [91]      |
|                                          | Many OATPs (SLCO family) expressed in insect cells                     |                                                                           | [90]      |
| Lucifer yellow                           | Sodium-dependent anion transporters                                   | Inhibited by probenecid                                                  | [151,152] |
| Rhodamine 123                            | OCT1/OCT2 (SLC22A1/2) | Potent substrate                                                         | [153]     |
| Stilbazolium dyes                        | Norepinephrine transporter (SLC6)                                     | Dyes related to ASP+                                                     | [154]     |
| Zombie Violet, Live/Dead Green, Cascade Blue, Alexa Fluor 405 | OATP (SLCO) 1B1/1B3 and 2B1 | All shown to be direct substrates, and uptake inhibited by known transporter inhibitors | [155]     |

Structural similarity (or the assessment of properties based simply on analyzing structures) is an elusive concept (e.g., [156,157]), but as judged by a standard encoding (RDKit Patterned), there is considerable similarity in structure between almost all of our chosen fluorophores and at least one drug.
whether this is judged by their descriptor- or fingerprint-based properties (Figures 1–3), by observation (Figures 4 and 6), or (Figure 5) via the QED [108] measure.

**UMAP visualisation of drugs, fluorophores, metabolites and natural products**

![UMAP projection into two dimensions of the four classes of molecules, annotated by the type of molecular structure in the various clusters.](image)

Figure 6. UMAP projection into two dimensions of the four classes of molecules, annotated by the type of molecular structure in the various clusters.

Although there is a move towards phenotypic screening [158–161], many drugs were developed on the basis of their ability to bind potently in vitro to a target of interest. If the unbound molecule is conformationally very flexible, and the bound version is not, binding necessarily involves a significant loss of entropy. Potent binding (involving a significant loss in free energy) of such a molecule would thus require a very large enthalpic term. Consequently, it is much easier to find potent binders if the binding can involve flat (which implies aromatic), conformationally inflexible planar structures. Such reasoning presumably reflects the observation (Figure 5B) that drugs tend to have a low sp$^3$ character, typically with a number of aromatic rings. Conjugated aromatic rings are also a major (physical and electronic) structure that allow fluorescence from organic molecules [162–165], with greater $\pi$-bond conjugation moving both absorbance and fluorescence toward the red end of the spectrum. Overall, these two separate roles for aromatic residues, in low entropy of binding and in electronic structure, provide a plausible explanation for much of the drug-likeness of common fluorophores.

While this study used a comparatively small set of fluorophores, increasing their number can only increase the likelihood of finding a drug (or natural product) to which they are seen to be similar. This said, this set of molecules provides an excellent starting point for the development of competitive high-throughput assays of drug transporter activity.

4. Materials and Methods

Fluorophores were selected from the literature and by scanning various catalogues of fluorophores, and included well known cytochemical stains, food dyes, laser dyes and other fluorophores, including just a few marketed drugs plus fluorescent natural products. We chose only those whose structures were known publicly. The final set included 150 molecules. Supplementary Fluorophores SI.xlsx gives a spreadsheet of all the relevant data that we discuss, including the marketed drugs, Recon2 metabolites [87] (both given also in Reference 37) and a subset of 2000 natural products from UNPD (see [55,85]).
Although there are a great many possible molecular encodings (whether using molecular fingerprints or vectors of calculated properties), each of which can give a different Tanimoto similarity, for our present purpose we chose to use only the Patterned encoding within RDKit (www.rdkit.org). We also used the RDKit version of QED (https://www.rdkit.org/docs/source/rdkit.Chem.QED.html). Workflows were written in KNIME as per our standard methods [45–48,55,84,166,167]. t-SNE plots used the first 10 PCs (95.3% explained variance) as inputs based on 27 RDKit descriptors, and were otherwise as previously described [168].

5. Conclusions

An analysis of some 150 fluorophores in common usage in biological research has shown that a great many of them bear significant structural similarities to marketed drugs (and to natural products). This similarity holds true whether the analysis is done using structures encoded as fingerprints or via physico-chemical descriptors, by visual inspection, or via the quantitative estimate of drug likeness measure. For any given drug, there is thus likely to be a fluorophore or set of fluorophores that is best suited to competing with it for uptake, and thus for determining, by fluorimetric methods, the QSAR for the relevant transporters. This should provide the means for rapid and convenient competitive and trans-stimulation assays for screening the ability of drugs to enter cells via SLCs.

Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/18/11/582/s1. Fluorophores SI.xlsx: The list of all the molecules and properties illustrated in the present analysis. The descriptors are taken from rdkit, and each of them is explained in detail, with relevant literature references, at https://www.rdkit.org/docs/GettingStartedInPython.html#list-of-available-descriptors.

Author Contributions: Conceptualization, S.O. and D.B.K.; methodology, S.O. and D.B.K.; software, S.O.; validation, S.O. and D.B.K.; resources, D.B.K.; data curation, S.O. and D.B.K.; writing—original draft preparation, S.O. and D.B.K.; writing—review and editing S.O. and D.B.K.; visualization, S.O. and D.B.K.; funding acquisition, D.B.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the UK BBSRC (grant BB/P009042/1) and the Novo Nordisk Foundation (grant NNF10CC1016517).

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

PCA Principal Components Analysis
QED Quantitative Estimate of Drug-likeness
QSAR Quantitative Structure–Activity Relationship
SLC solute carrier
TS Tanimoto similarity
UNPD Universal Natural Products Database

References

1. Chalfie, M.; Kain, S. Green Fluorescent Protein: Properties, Applications, and Protocols; Wiley-Liss: New York, NY, USA, 1998.
2. Hemmilä, I.A. Applications of Fluorescence in Immunoassays; Wiley: New York, NY, USA, 1991.
3. Waggoner, A.S. Fluorescent probes for cytometry. In Flow Cytometry and Sorting, 2nd ed.; Melamed, M.R., Lindmo, T., Mendelsohn, M.L., Eds.; Wiley-Liss Inc.: New York, NY, USA, 1990; pp. 209–225.
4. Kyrychenko, A. Using fluorescence for studies of biological membranes: A review. Methods Appl. Fluoresc. 2015, 3, 042003. [PubMed]
5. Lagorio, M.G.; Cordon, G.B.; Iriel, A. Reviewing the relevance of fluorescence in biological systems. Photochem. Photobiol. Sci. 2015, 14, 1538–1559. [PubMed]
6. Specht, E.A.; Braselmann, E.; Palmer, A.E. A critical and comparative review of fluorescent tools for live-cell imaging. Annu. Rev. Physiol. 2017, 79, 93–117. [PubMed]
7. Sahl, S.J.; Hell, S.W.; Jakobs, S. Fluorescence nanoscopy in cell biology. Nat. Rev. Mol. Cell Biol. 2017, 18, 685–701. [PubMed]
8. Mavrakis, M.; Pourquie, O.; Lecuit, T. Lighting up developmental mechanisms: How fluorescence imaging heralded a new era. Development 2010, 137, 373–387. [PubMed]
9. Johnson, I. Fluorescent probes for living cells. Histochem. J. 1998, 30, 123–140. [PubMed]
10. Kolanowski, J.L.; Liu, F.; New, E.J. Fluorescent probes for the simultaneous detection of multiple analytes in biology. Chem. Soc. Rev. 2018, 47, 195–208.
11. Zhang, J.; Campbell, R.E.; Ting, A.Y.; Tsien, R.Y. Creating new fluorescent probes for cell biology. Nat. Rev. Mol. Cell Biol. 2002, 3, 906–918.
12. Jiang, X.; Wang, L.; Carroll, S.L.; Chen, J.; Wang, M.C.; Wang, J. Challenges and opportunities for small-molecule fluorescent probes in redox biology applications. Antioxid. Redox Signal. 2018, 29, 518–540.
13. Winterbourn, C.C. The challenges of using fluorescent probes to detect and quantify specific reactive oxygen species in living cells. Biochim. Biophys. Acta 2014, 1840, 730–738.
14. Davey, H.M.; Kell, D.B. Flow cytometry and cell sorting of heterogeneous microbial populations: The importance of single-cell analysis. Microbiol. Rev. 1996, 60, 641–696. [PubMed]
15. Shapiro, H.M. Practical Flow Cytometry, 3rd ed.; John Wiley: New York, NY, USA, 2003.
16. Lavis, L.D.; Raines, R.T. Bright ideas for chemical biology. ACS Chem. Biol. 2008, 3, 142–155. [PubMed]
17. Kell, D.B. A Protet-Based, Protonic Charge Transfer Model of Energy Coupling in Oxidative and Photosynthetic Phosphorylation. OSF Preprint. 2020. Available online: http://osf.io/2xs28 (accessed on 23 November 2020).
18. Salcedo-Sora, J.E.; Jindal, S.; O’Haagan, S.; Kell, D.B. A palette of fluorophores that are differentially accumulated by wild-type and mutant strains of Escherichia coli: Surrogate ligands for bacterial membrane transporters. bioRxiv 2020. [CrossRef]
19. Karasev, M.M.; Stepanenko, O.V.; Rumyantsev, K.A.; Turoverov, K.K.; Verkhusha, V.V. Near-infrared fluorescent proteins and their applications. Biochemistry (Moscow) 2019, 84, S52–S50.
20. Liu, W.F.; Deng, M.Y.; Yang, C.M.; Liu, F.; Guan, X.M.; Du, Y.C.; Wang, L.; Chu, J. Genetically encoded single circularly permuted fluorescent protein-based intensity indicators. J. Phys. D 2020, 53, 113001.
21. Pedelacq, J.D.; Cabantous, S. Development and applications of superfolder and split fluorescent protein detection systems in biology. Int. J. Mol. Sci. 2019, 20, 3479.
22. Shcherbakova, D.M.; Stepanenko, O.V.; Turoverov, K.K.; Verkhusha, V.V. Near-infrared fluorescent proteins: Multiplexing and optogenetics across scales. Trends Biotechnol. 2018, 36, 1230–1243.
23. Jindal, S.; Yang, L.; Day, P.J.; Kell, D.B. Involvement of multiple influx and efflux transporters in the accumulation of cationic fluorescent dyes by Escherichia coli. BMC Microbiol. 2019, 19, 195.
24. Kell, D.B. Control of metabolite efflux in microbial cell factories: Current advances and future prospects. In Fermentation Microbiology and Biotechnology, 4th ed.; El-Mansi, E.M.T., Nielsen, J., Mousdale, D., Allman, T., Carlson, R., Eds.; CRC Press: Boca Raton, FL, USA, 2019; pp. 117–138.
25. Szakács, G.; Váradi, A.; Özvégyn-Laczka, C.; Sarkadi, B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov. Today 2008, 13, 379–393.
26. Schinkel, A.H.; Jonker, J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv. Drug Del. Rev. 2012, 64, 138–153.
27. Tarling, E.J.; de Aguia Vallim, T.Q.; Edwards, P.A. Role of ABC transporters in lipid transport and human disease. Trends Endocrinol. Metab. 2013, 24, 342–350. [PubMed]
28. Andreoletti, P.; Raas, Q.; Gondcaille, C.; Cherkaoui-Malki, M.; Trompier, D.; Savary, S. Predictive structure and topology of peroxisomal ATP-binding cassette (ABC) transporters. Int. J. Mol. Sci. 2017, 18, 1593.
29. Sharom, F.J. ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 2008, 9, 105–127.
30. Pahnke, J.; Fröhlich, C.; Paarmann, K.; Krohn, M.; Bogdanovic, N.; Årsland, D.; Winblad, B. Cerebral ABC transporter-common mechanisms may modulate neurodegenerative diseases and depression in elderly subjects. Arch. Med. Res. 2014, 45, 738–743. [PubMed]
31. Abuznait, A.H.; Kaddoumi, A. Role of ABC transporters in the pathogenesis of alzheimer’S disease. ACS Chem. Neurosci. 2012, 3, 820–831. [PubMed]
32. Lam, F.C.; Liu, R.; Lu, P.; Shapiro, A.B.; Renoir, J.M.; Sharom, F.J.; Reiner, P.B. Beta-amyloid efflux mediated by P-glycoprotein. J. Neurochem. 2001, 76, 1121–1128. [PubMed]
33. Molnar, J.; Oseovszki, I.; Pusztai, R. Amyloid-beta interactions with ABC transporters and resistance modifiers. Anticancer Res. 2018, 38, 3407–3410.
34. Wijnholds, J.; Evers, R.; van Leusden, M.R.; Mol, C.A.A.M.; Zaman, G.J.R.; Mayer, U.; Beijnen, J.H.; van der Valk, M.; Krümpenfort, P.; Borst, P. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. *Nat. Med.* 1997, 3, 1275–1279. [PubMed]

35. Prates, R.A.; Kato, I.T.; Ribeiro, M.S.; Tegos, G.P.; Hamblin, M.R. Influence of multidrug efflux systems on methylene blue-mediated photodynamic inactivation of *Candida albicans*. *J. Antimicrob. Chemother.* 2011, 66, 1525–1532. [PubMed]

36. Forster, S.; Thumser, A.E.; Hood, S.R.; Plant, N. Characterization of rhodamine-123 as a tracer dye for use in *in vitro* drug transport assays. *PLoS ONE* 2012, 7, e33253.

37. Ivnitski-Steele, I.; Holmes, A.R.; Lamping, E.; Monk, B.C.; Cannon, R.D.; Sklar, L.A. Identification of Nile red as a fluorescent substrate of the *Candida albicans* ATP-binding cassette transporters cdr1p and cdr2p and the major facilitator superfamily transporter mdr1p. *Anal. Biochem.* 2009, 384, 87–91. [PubMed]

38. Strouse, J.J.; Ivnitski-Steele, I.; Waller, A.; Young, S.M.; Perez, D.; Evangelisti, A.M.; Ursu, O.; Bologa, C.G.; Carter, M.B.; Salas, V.M.; et al. Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters. *Anal. Biochem.* 2013, 437, 77–87. [PubMed]

39. Kell, D.B. Control of Metabolite Efflux in Microbial Cell Factories: Current Advances and Future Prospects. Available online: https://osf.io/xg9jh (accessed on 8 November 2020).

40. Szabó, E.; Türk, D.; Telbisz, Á.; Kucsma, N.; Horváth, T.; Szakács, G.; Homolya, L.; Sarkan, B.; Várády, G. A new fluorescent dye accumulation assay for parallel measurements of the ABCG2, ABCB1 and ABCC1 multidrug transporter functions. *PLoS ONE* 2018, 13, e0190629.

41. Gökirmak, T.; Shipp, L.E.; Campanale, J.P.; Nicklisch, S.C.T.; Hamdoun, A. Transport in technicolor: Mapping ATP-binding cassette transporters in sea urchin embryos. *Mol. Reprod. Dev.* 2014, 81, 778–793.

42. Fardel, O.; Le Vee, M.; Jouan, E.; Denizot, C.; Parmentier, Y. Nature and uses of fluorescent dyes for drug transporter studies. *Expert Opin. Drug Metab. Toxicol.* 2015, 11, 1233–1251.

43. Fredriksson, R.; Nordström, K.J.; Stephansson, O.; Hägglund, M.G.; Schiöth, H.B. The solute carrier (SLC) complement of the human genome: Phylogenetic classification reveals four major families. *FEBS Lett.* 2008, 582, 3811–3816.

44. Darbani, B.; Kell, D.B.; Borodina, I. Energetic evolution of cellular transportomes. *BMC Genom.* 2018, 19, 418.

45. O’Hagan, S.; Swainston, N.; Handl, J.; Kell, D.B. A ‘rule of 0.5’ for the metabolite-likeness of approved pharmaceutical drugs. *Metabolomics* 2015, 11, 323–339.

46. O’Hagan, S.; Kell, D.B. Understanding the foundations of the structural similarities between marketed drugs and endogenous human metabolites. *Front. Pharmacol.* 2015, 6, 105.

47. O’Hagan, S.; Kell, D.B. Metmaxstruct: A Tversky-similarity-based strategy for analysing the (sub)structural similarities of drugs and endogenous human metabolites. *Front. Pharmacol.* 2016, 7, 266.

48. O’Hagan, S.; Kell, D.B. Analysis of drug-endogenous human metabolite similarities in terms of their maximum common substructures. *J. Cheminform.* 2017, 9, 18. [PubMed]

49. Nigam, S.K. What do drug transporters really do? *Nat. Rev. Drug Discov.* 2015, 14, 29–44. [PubMed]

50. Girardi, E.; César-Razquin, A.; Lindinger, S.; Papakostas, K.; Lindinger, S.; Konecka, J.; Hemmerich, J.; Kickinger, S.; Kartnig, F.; Gürtl, B.; et al. A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs. *Nat. Chem. Biol.* 2016, 20, 469–478. [PubMed]

51. Pizzagalli, M.D.; Bensimon, A.; Superti-Furga, G. A guide to plasma membrane solute carrier proteins. *FEBS J.* 2020. [CrossRef]

52. Superti-Furga, G.; Lackner, D.; Wiedmer, T.; Ingles-Prieto, A.; Barbosa, B.; Girardi, E.; Goldman, U.; Gürtl, B.; Klavins, K.; Klimek, C. The RESOLUTE consortium: Unlocking SLC transporters for drug discovery. *Nat. Rev. Drug Discov.* 2020, 19, 429–430.

53. Kell, D.B. Hitchhiking into the cell. *Nat. Chem. Biol.* 2020, 16, 367–368.

54. Gründemann, D.; Harlfinger, S.; Golz, S.; Geerts, A.; Lazar, A.; Berkers, R.; Jung, N.; Rubbert, A.; Schömig, E. Discovery of the ergothioneine transporter. *Proc. Natl. Acad. Sci. USA* 2005, 102, 5256–5261.

55. O’Hagan, S.; Kell, D.B. Consensus rank orderings of molecular fingerprints illustrate the ‘most genuine’ similarities between marketed drugs and small endogenous human metabolites, but highlight exogenous natural products as the most important ‘natural’ drug transporter substrates. *ADMET DMPK* 2017, 5, 85–125.

56. Gautier, J.; Munnier, E.; Souce, M.; Chourpa, L.; Douziech Eyrolles, L. Analysis of doxorubicin distribution in mcf-7 cells treated with drug-loaded nanoparticles by combination of two fluorescence-based techniques, confocal spectral imaging and capillary electrophoresis. *Anal. Bioanal. Chem.* 2015, 407, 3425–3435.
81. O’Hagan, S.; Kell, D.B. Structural similarities between some common fluorophores used in biology and marketed drugs, endogenous metabolites, and natural products. *bioRxiv* 2019, 2019, 834325.

82. van der Maaten, L.; Hinton, G. Visualizing data using t-SNE. *J. Mach. Learn. Res.* 2008, 9, 2579–2605.

83. Thiele, I.; Heinken, A.; Fleming, R.M. A systems biology approach to studying the role of microbes in human health. *Curr. Opin. Biotechnol.* 2013, 24, 4–12.

84. O’Hagan, S.; Kell, D.B. Analysing and navigating natural products space for generating small, diverse, but representative chemical libraries. *Biotechnol. J.* 2018, 13, 1700503.

85. Gu, J.Y.; Gui, Y.S.; Chen, L.R.; Yuan, G.; Lu, H.Z.; Xu, X.J. Use of natural products as chemical library for drug discovery and network pharmacology. *PLoS ONE* 2013, 8, e62839.

86. Eisen, M.B.; Spellman, P.T.; Brown, P.O.; Botstein, D. Cluster analysis and display of genome-wide expression patterns. *Proc. Natl. Acad. Sci. USA* 1998, 95, 14863–14868.

87. Thiele, I.; Swainston, N.; Fleming, R.M.T.; Hoppe, A.; Sahoo, S.; Aurich, M.K.; Haraldsdóttir, H.; Mo, M.L.; Rolfsønn, O.; Stobbe, M.D.; et al. A community-driven global reconstruction of human metabolism. *Nat. Biotechnol.* 2013, 31, 419–425.

88. Bakkar, M.M.; Hardaker, L.; March, P.; Morgan, P.B.; Maldonado-Codina, C.; Dobson, C.B. The cellular basis for biocide-induced fluorescein hyperfluorescence in mammalian cell culture. *PLoS ONE* 2014, 9, e84427.

89. Khan, T.F.; Price, B.L.; Morgan, P.B.; Maldonado-Codina, C.; Dobson, C.B. Cellular fluorescein hyperfluorescence is dynamin-dependent and increased by tetrionate 1107 treatment. *Int. J. Biochem. Cell Biol.* 2018, 101, 54–63. [PubMed]

90. Patil, S.A.; Sun, H.; Tawa, G.; Wallqvist, A. Classification of scaffold hopping. *Expert Opin. Drug Discov.* 2008, 13, 282–292. [PubMed]

91. Blair, H.A. Tolvaptan: A review in autosomal dominant polycystic kidney disease. *Drugs* 2019, 79, 303–313. [PubMed]

92. O’Hagan, S.; Moss, A.C. Balsalazide disodium for the treatment of ulcerative colitis. *Expert Rev. Gastroenterol. Hepatol.* 2008, 2, 177–184.

93. van der Maaten, L.; Hinton, G. Visualizing data using t-SNE. *J. Mach. Learn. Res.* 2008, 9, 2579–2605.

94. Thiele, I.; Heinken, A.; Fleming, R.M. A systems biology approach to studying the role of microbes in human health. *Curr. Opin. Biotechnol.* 2013, 24, 4–12.

95. Patil, S.A.; Moss, A.C. Balsalazide disodium for the treatment of ulcerative colitis. *Expert Rev. Gastroenterol. Hepatol.* 2008, 2, 177–184.

96. Egesel, T.; Ünsal, I.; Dikmen, G.; Bayraktar, Y. The assessment of pancreatic exocrine function by bentiromide test in patients with chronic portal vein thrombosis. *Pancreas* 2002, 25, 355–359.

97. Singal, A. Butenafine and superficial mycoses: Current status. *Expert Opin. Drug Metab. Toxicol.* 2008, 4, 999–1005.

98. Blair, H.A. Tolvaptan: A review in autosomal dominant polycystic kidney disease. *Drugs* 2019, 79, 303–313. [PubMed]

99. Brown, N.; Jacoby, E. On scaffolds and hopping in medicinal chemistry. *Mini Rev. Med. Chem.* 2006, 6, 1217–1229. [PubMed]

100. Geppert, H.; Bajorath, J. Advances in 2d fingerprint similarity searching. *Expert Opin. Drug Discov.* 2010, 5, 529–542. [PubMed]

101. Lamberth, C. Agrochemical lead optimization by scaffold hopping. *Pest Manag. Sci.* 2018, 74, 282–292. [PubMed]

102. Mauser, H.; Guba, W. Recent developments in *de novo* design and scaffold hopping. *Curr. Opin. Drug Discov. Dev.* 2008, 11, 365–374.

103. Zhao, H. Scaffold selection and scaffold hopping in lead generation: A medicinal chemistry perspective. *Drug Disc. Today* 2007, 12, 149–155.
Das, A.M. Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (ht-1). *Appl. Clin. Genet* 2017, 10, 43–48.

Lock, E.; Ranganath, L.R.; Timmis, O. The role of nitisinone in tyrosine pathway disorders. *Curr. Rheumatol. Rep.* 2014, 16, 457.

Ranganath, L.R.; Khedr, M.; Milan, A.M.; Davison, A.S.; Hughes, A.T.; Usher, J.L.; Taylor, S.; Loftus, N.; Daroszewska, A.; West, E.; et al. Nitisinone arrests ochronosis and decreases rate of progression of alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom national alkaptonuria centre. *Mol. Genet. Metab.* 2018, 125, 127–134.

Bickerton, G.R.; Paolini, G.V.; Besnard, J.; Muresan, S.; Hopkins, A.L. Quantifying the chemical beauty of drugs. *Nat. Chem.* 2012, 4, 90–98. [PubMed]

Shultz, M.D. Two decades under the influence of the rule of five and the changing properties of approved oral drugs. *J. Med. Chem.* 2019, 62, 1701–1714. [PubMed]

Lovering, F.; Bikker, J.; Humblet, C. Escape from flatland: Increasing saturation as an approach to improving clinical success. *J. Med. Chem.* 2009, 52, 6752–6756. [PubMed]

Meyers, J.; Carter, M.; Mok, N.Y.; Brown, N. On the origins of three-dimensionality in drug-like molecules. *Future Med. Chem.* 2016, 8, 1753–1767.

Campbell, P.S.; Jamieson, C.; Simpson, I.; Watson, A.J.B. Practical synthesis of pharmaceutically relevant molecules enriched in sp(3) character. *Chem. Commun. (Camb.)* 2017, 54, 46–49.

Blakemore, D.C.; Castro, L.; Churcher, I.; Rees, D.C.; Thomas, A.W.; Wilson, D.M.; Wood, A. Organic synthesis provides opportunities to transform drug discovery. *Nat. Chem.* 2010, 18, 383–394.

Boström, J.; Brown, D.G.; Young, R.J.; Keserü, G.M. Expanding the medicinal chemistry synthetic toolbox. *Nat. Rev. Drug Discov.* 2018, 17, 709–727.

Yuan, L.; Lin, W.; Zheng, K.; He, L.; Huang, W. Far-red to near infrared analyte-responsive fluorescent probes based on organic fluorophore platforms for fluorescence imaging. *Chem. Soc. Rev.* 2013, 42, 622–661.

McInnes, L.; Healy, J.; Melville, J. UMAP: Uniform manifold approximation and projection for dimension reduction. *arXiv* 2018, arXiv:1802.03426.

McInnes, L.; Healy, J.; Saul, N.; Großberger, L. Umap: Uniform manifold approximation and projection. *J. Open Source Softw.* 2018. [CrossRef]

Koehn, F.E.; Carter, G.T. The evolving role of natural products in drug discovery. *Nat. Rev. Drug Discov.* 2005, 4, 206–220. [PubMed]

Dobson, P.D.; Patel, Y.; Kell, D.B. “Metabolite-likeness” as a criterion in the design and selection of pharmaceutical drug libraries. *Drug Disc. Today* 2009, 14, 31–40.

Doak, B.C.; Over, B.; Giordanetto, F.; Kihlberg, J. Oral druggable space beyond the rule of 5: Insights from drugs and clinical candidates. *Chem. Biol.* 2014, 21, 1115–1142. [PubMed]

Quinn, R.J.; Carroll, A.R.; Pham, N.B.; Baron, P.; Palfraiman, M.E.; Suraweera, L.; Pierens, G.K.; Muresan, S. Developing a drug-like natural product library. *J. Nat. Prod.* 2008, 71, 464–468.

Krämer, S.D.; Aschmann, H.E.; Hatibovic, M.; Hermann, K.F.; Neuhaus, C.S.; Brunner, C.; Belli, S. When barriers ignore the “rule-of-five”. *Adv. Drug Deliv. Rev.* 2016, 101, 62–74.

Guimarães, C.R.W.; Mathiowetz, A.M.; Shalaeva, M.; Goetz, G.; Liras, S. Use of 3d properties to characterize beyond rule-of-5 property space for passive permeation. *J. Chem. Inf. Model.* 2012, 52, 882–890.

Leeson, P.D. Molecular inflation, attrition and the rule of five. *Adv. Drug Deliv. Rev.* 2016, 101, 22–33.

DeGoey, D.A.; Chen, H.J.; Cox, P.B.; Wendt, M.D. Beyond the rule of 5: Lessons learned from abbbie’s drugs and compound collection. *J. Med. Chem.* 2018, 61, 2636–2651.

Chen, Y.; Garcia de Lomana, M.; Friedrich, N.O.; Kirchmair, J. Characterization of the chemical space of known and readily obtainable natural products. *J. Chem. Inf. Model.* 2018, 58, 1518–1532.

Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *J. Nat. Prod.* 2020, 83, 770–803.

Ivnitski-Steele, I.; Larson, R.S.; Lovato, D.M.; Kawajwa, H.M.; Winter, S.S.; Oprea, T.I.; Sklar, L.A.; Edwards, B.S. High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters. *Assay Drug Dev. Technol.* 2008, 6, 263–276. [PubMed]

Tegos, G.P.; Evangelisti, A.M.; Strouse, J.J.; Ursu, O.; Bologa, C.; Sklar, L.A. A high throughput flow cytometric assay platform targeting transporter inhibition. *Drug Disc. Today Technol.* 2014, 12, e95–e103.
151. Masereeuw, R.; Moons, M.M.; Toomey, B.H.; Russel, F.G.M.; Miller, D.S. Active lucifer yellow secretion in renal proximal tubule: Evidence for organic anion transport system crossover. *J. Pharmacol. Exp. Ther.* 1999, 289, 1104–1111.

152. de Gier, R.P.E.; Feitz, W.F.J.; Masereeuw, R.; Wouterse, A.C.; Smits, D.; Russel, F.G.M. Anionic and cationic drug secretion in the isolated perfused rat kidney after neonatal surgical induction of ureteric obstruction. *BJU Int.* 2003, 92, 452–458.

153. Jouan, E.; Le Vee, M.; Denizot, C.; Da Violante, G.; Fardel, O. The mitochondrial fluorescent dye rhodamine 123 is a high-affinity substrate for organic cation transporters (OCTs) 1 and 2. *Fundam Clin. Pharmacol.* 2014, 28, 65–77.

154. Wilson, J.N.; Brown, A.S.; Babinchak, W.M.; Ridge, C.D.; Walls, J.D. Fluorescent stilbazolium dyes as probes of the norepinephrine transporter: Structural insights into substrate binding. *Org. Biomol. Chem.* 2012, 10, 8710–8719.

155. Patik, I.; Székely, V.; Németh, O.; Kucsma, Á.; Szakács, G.; Bakos, É.; Özvegy-Laczka, C. Identification of novel cell-impermeant fluorescent substrates for testing the function and drug interaction of organic anion-transporting polypeptides, OATP1B1/1B3 and 2B1. *Sci. Rep.* 2018, 8, 2630.

156. Lajiness, M.S.; Maggiora, G.M.; Shanmugasundaram, V. Assessment of the consistency of medicinal chemists in reviewing sets of compounds. *J. Med. Chem.* 2004, 47, 4891–4896.

157. Samanta, S.; O’Hagan, S.; Swainston, N.; Roberts, T.J.; Kell, D.B. Vae-sim: A novel molecular similarity measure based on a variational autoencoder. *Molecules* 2020, 25, 3446.

158. Kell, D.B. Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening, and knowledge of transporters: Where drug discovery went wrong and how to fix it. *FEBS J.* 2013, 280, 5957–5980. [PubMed]

159. Kell, D.B.; Wright Muelas, M.; O’Hagan, S.; Day, P.J. The role of drug transporters in phenotypic screening. *Drug Target Rev.* 2018, 4, 16–19.

160. Prior, M.; Chiruta, C.; Currais, A.; Goldberg, J.; Ramsey, J.; Dargusch, R.; Maher, P.A.; Schubert, D. Back to the future with phenotypic screening. *ACS Chem. Neurosci.* 2014, 5, 503–513. [PubMed]

161. Swinney, D.C. Opportunities for phenotypic screening in drug discovery. *Drug Disc. World* 2014, 15, 33–42.

162. Yamaguchi, Y.; Matsubara, Y.; Ochi, T.; Wakamiya, T.; Yoshida, Z. How the π conjugation length affects the fluorescence emission efficiency. *J. Am. Chem. Soc.* 2008, 130, 13867–13869.

163. Lavis, L.D.; Raines, R.T. Bright building blocks for chemical biology. *ACS Chem. Biol.* 2014, 9, 855–866.

164. Zambianchi, M.; Di Maria, F.; Cazzato, A.; Gigli, G.; Piacenza, M.; Della Sala, F.; Barbarella, G. Microwave-assisted synthesis of thiophene fluorophores, labeling and multilabeling of monoclonal antibodies, and long lasting staining of fixed cells. *J. Am. Chem. Soc.* 2009, 131, 10892–10900.

165. Di Maria, F.; Palamà, I.E.; Baroncini, M.; Barbieri, A.; Bongini, A.; Bizzarri, R.; Gigli, G.; Barbarella, G. Live cell cytoplasm staining and selective labeling of intracellular proteins by non-toxic cell-permeant thiophene fluorophores. *Org. Biomol. Chem.* 2014, 12, 1603–1610.

166. O’Hagan, S.; Kell, D.B. The KNIME workflow environment and its applications in genetic programming and machine learning. *Genet. Progr. Evol. Mach.* 2015, 16, 387–391.

167. O’Hagan, S.; Kell, D.B. The apparent permeabilities of caco-2 cells to marketed drugs: Magnitude, and independence from both biophysical properties and endogenite similarities. *PeerJ* 2015, 3, e1405.

168. O’Hagan, S.; Kell, D.B. Generation of a small library of natural products designed to cover chemical space inexpensively. *Pharm. Front.* 2019, 1, e190005. [PubMed]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.